#USA #Prague #EMFACE #BTL Group #WonderFace

BTL Group Achieves Significant Patent Victory Over WonderFace

The BTL Group, a global frontrunner in the medical technology sector, has recently announced a substantial endorsement of its intellectual property rights concerning its advanced EMFACE® technology. This victory stems from the successful resolution of several patent infringement cases against Lexter Microelectronic Engineering Systems S.L., the manufacturer of the WonderFace device.

The legal proceedings were initiated to safeguard BTL's proprietary innovations, which are central to the EMFACE® technology known for its efficacy in non-invasive facial treatments. As a result of the settlement, Lexter has agreed to cease all production, distribution, and utilization of facial treatment technologies that integrate radiofrequency and electrical muscle stimulation, a clear affirmation of BTL's rights to its patented solutions.

Tomas Schwarz, the CEO of BTL Group, highlighted the significance of this outcome, stating, "The global and conclusive effect of this agreement exemplifies our commitment to defending BTL's intellectual property and protecting the investments of our clients." The emphasis on strong patent rights not only reinforces BTL's market position but also instills confidence among its users and stakeholders regarding the future of its innovative technologies.

Founded in 1993, BTL Group has established itself as a pioneering force in medical device innovation, boasting a comprehensive portfolio of over 200 patents and a dedicated team of over 600 internal engineers. The company's commitment to utilizing science and technology to deliver non-invasive and therapeutic medical treatments is reflected in its diverse product offerings, including EMFACE®, EMSCULPT NEO®, and EMSELLA®.

The EMFACE® product line is especially notable for its dual-action technology, combining electrical muscle stimulation with radiofrequency, facilitating effective non-invasive facial contouring and skin rejuvenation treatments. This technology has become increasingly popular among practitioners and patients seeking high-quality aesthetic medical solutions.

The outcome against Lexter is not only a testament to BTL's rigorous enforcement of its patent rights but also sends a strong message throughout the industry regarding the importance of protecting innovation in the highly competitive medical technology landscape. BTL's proactive approach to patent enforcement underscores its dedication to fostering a marketplace where innovative solutions can thrive without infringement or compromise.

As BTL continues to innovate and expand its offerings, the company remains dedicated to maintaining the integrity of its patented technologies. To learn more about EMFACE® and BTL's other innovative medical devices, visit www.emface.com. This settlement marks a pivotal moment in BTL's journey, affirming its position as a leader in medical innovations focused on enhancing patient care and satisfaction.

The BTL Group’s future looks bright as it forges ahead, continuously exploring new avenues for innovation while ensuring that its value to clients and patients remains uncompromised. As the industry evolves, BTL stands ready to face new challenges, armed with a robust patent portfolio and unwavering commitment to excellence.